Compare
Aldeyra Therapeutics, Inc. vs Incannex Healthcare Inc. vs Corvus Pharmaceuticals, Inc. vs Inovio Pharmaceuticals, Inc.
| Latest fiscal year | Aldeyra Therapeutics, Inc. ALDX | Incannex Healthcare Inc. IXHL | Corvus Pharmaceuticals, Inc. CRVS | Inovio Pharmaceuticals, Inc. INO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | n/a | $65.3K |
| Revenue growth (YoY) | n/a | -100.0% | n/a | -70.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$33.85M | -$19.30M | -$15.28M | -$84.95M |
| EPS (Diluted) | -$0.56 | -$1.66 | -$0.53 | -$1.81 |
| Operating cash flow | -$33.35M | -$12.87M | -$32.80M | -$88.63M |
| Free cash flow | n/a | -$12.88M | -$32.97M | -$88.92M |
| Cash & equivalents | $70.04M | $67.71M | $4.58M | $44.27M |
| Total assets | $72.06M | $72.98M | $71.12M | $74.31M |
| Total liabilities | $27.81M | $5.61M | $9.91M | $50.21M |
| Shareholders' equity | $44.25M | $67.37M | $61.20M | $24.10M |
| Return on year-end equity | -76.5% | -28.6% | -25.0% | -352.5% |
| Shares outstanding | 60.16M | 12.54M | 74.70M | 69.00M |
Revenue, most recent five fiscal years
| Fiscal year | Aldeyra Therapeutics, Inc. | Incannex Healthcare Inc. | Corvus Pharmaceuticals, Inc. | Inovio Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2026-06-30 | n/a | $65.3K Ended 2025-12-31 |
| 1 year earlier | n/a | $86.0K Ended 2025-06-30 | n/a | $217.8K Ended 2024-12-31 |
| 2 years earlier | n/a | $12.0K Ended 2024-06-30 | n/a | $832.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $10.26M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $1.77M Ended 2021-12-31 |